Page 97 - Read Online

Page 274 Thomas et al. J Transl Genet Genom 2024;8:249-77 https://dx.doi.org/10.20517/jtgg.2024.15

188. González-González L, Alonso J. Periostin: a matricellular protein with multiple functions in cancer development and progression.
Front Oncol 2018;8:225. DOI PubMed PMC
+
189. Wei T, Wang K, Liu S, et al. Periostin deficiency reduces PD-1 tumor-associated macrophage infiltration and enhances anti-PD-1
efficacy in colorectal cancer. Cell Rep 2023;42:112090. DOI
190. Mortezaee K. Immune escape: a critical hallmark in solid tumors. Life Sci 2020;258:118110. DOI PubMed
191. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug
Discov 2019;18:197-218. DOI PubMed
192. Hussein MR, Al-Assiri M, Musalam AO. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign
nodular prostatic hyperplasia and prostatic adenocarcinoma. Exp Mol Pathol 2009;86:108-13. DOI PubMed
193. von Amsberg G, Alsdorf W, Karagiannis P, et al. Immunotherapy in advanced prostate cancer-light at the end of the tunnel? Int J Mol
Sci 2022;23:2569. DOI PubMed PMC
194. Anker JF, Naseem AF, Mok H, Schaeffer AJ, Abdulkadir SA, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic
clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 2018;9:1591. DOI PubMed PMC
195. Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint
inhibitors. J Immunother Cancer 2018;6:157. DOI PubMed PMC
196. Wang I, Song L, Wang BY, Rezazadeh Kalebasty A, Uchio E, Zi X. Prostate cancer immunotherapy: a review of recent
advancements with novel treatment methods and efficacy. Am J Clin Exp Urol 2022;10:210-33. PubMed PMC
197. Ma Z, Zhang W, Dong B, et al. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-
based immunotherapy. Theranostics 2022;12:4965-79. DOI PubMed PMC
198. Chesner L, Graff J, Polesso F, et al. Abstract B041: AR suppresses MHC class I expression and T-cell response in prostate cancer.
Cancer Res 2023;83:B041. DOI
199. Kogan-Sakin I, Cohen M, Paland N, et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to
epithelia-secreted IL-1. Carcinogenesis 2009;30:698-705. DOI
200. Tse BW, Scott KF, Russell PJ. Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. Prostate Cancer
2012;2012:128965. DOI PubMed PMC
201. Smith BN, Mishra R, Billet S, et al. Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical
benefit. Mol Ther 2023;31:78-89. DOI PubMed PMC
202. Zhou C, Gao Y, Ding P, Wu T, Ji G. The role of CXCL family members in different diseases. Cell Death Discov 2023;9:212. DOI
PubMed PMC
203. Bullock K, Richmond A. Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the
efficacy of immunotherapy. Cancers 2021;13:6293. DOI PubMed PMC
204. Korbecki J, Kupnicka P, Chlubek M, Gorący J, Gutowska I, Baranowska-Bosiacka I. CXCR2 receptor: regulation of expression,
signal transduction, and involvement in cancer. Int J Mol Sci 2022;23:2168. DOI PubMed PMC
205. Di Mitri D, Mirenda M, Vasilevska J, et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence
and tumor inhibition in advanced prostate cancer. Cell Rep 2019;28:2156-2168.e5. DOI PubMed PMC
206. Bahig H, Taussky D, Delouya G, et al. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer
2015;15:594. DOI PubMed PMC
207. Sharma J, Gray KP, Harshman LC, et al. Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-
deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. Prostate 2014;74:820-8.
DOI
208. Minas TZ, Candia J, Dorsey TH, et al. Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer.
Nat Commun 2022;13:1759. DOI PubMed PMC
209. Wallace TA, Prueitt RL, Yi M, et al. Tumor immunobiological differences in prostate cancer between African-American and
European-American men. Cancer Res 2008;68:927-36. DOI
210. Zhu W, Wu J, Huang J, et al. Multi-omics analysis reveals a macrophage-related marker gene signature for prognostic prediction,
immune landscape, genomic heterogeneity, and drug choices in prostate cancer. Front Immunol 2023;14:1122670. DOI PubMed
PMC
211. Chen C, Luo J, Wang X. Identification of prostate cancer subtypes based on immune signature scores in bulk and single-cell
transcriptomes. Med Oncol 2022;39:123. DOI PubMed
212. Guo T, Wang J, Yan S, et al. A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response
in prostate cancer. Front Endocrinol 2022;13:1037099. DOI PubMed PMC
213. Ren C, Wang Q, Wang S, et al. Metabolic syndrome-related prognostic index: predicting biochemical recurrence and differentiating
between cold and hot tumors in prostate cancer. Front Endocrinol 2023;14:1148117. DOI PubMed PMC
214. Li N, Yu K, Lin Z, Zeng D. Development of a novel immune subtyping system expanded with immune landscape and an 11-gene
signature for predicting prostate cancer survival. J Oncol 2022;2022:1183173. DOI PubMed PMC
215. Keam SP, Halse H, Nguyen T, et al. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. J
Immunother Cancer 2020;8:e000792. DOI PubMed PMC
216. Shen Y, Xu H, Long M, et al. Screening to identify an immune landscape-based prognostic predictor and therapeutic target for
prostate cancer. Front Oncol 2021;11:761643. DOI PubMed PMC